格隆汇10月30日丨信达生物(01801.HK)发布公告,2025年第三季度,公司共取得总产品收入超人民币33亿元,同比保持约40%的强劲增长,得益于肿瘤和综合管线双轮驱动共同发力:1)公司在肿瘤治疗领域保持领先地位,产品组合优势显著,达伯舒®(信迪利单抗注射液)等主要产品稳健增长,创新产品收入贡献占比进一步提升;2)综合产品线潜力快速释放,贡献增长新驱动力:信尔美®(玛仕度肽注射液)、信必乐®(...
Source Link格隆汇10月30日丨信达生物(01801.HK)发布公告,2025年第三季度,公司共取得总产品收入超人民币33亿元,同比保持约40%的强劲增长,得益于肿瘤和综合管线双轮驱动共同发力:1)公司在肿瘤治疗领域保持领先地位,产品组合优势显著,达伯舒®(信迪利单抗注射液)等主要产品稳健增长,创新产品收入贡献占比进一步提升;2)综合产品线潜力快速释放,贡献增长新驱动力:信尔美®(玛仕度肽注射液)、信必乐®(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.